Evidence for formation of a narrow pKshort resonance with mass near 1533 MeV in neutrino interactions

A narrow baryon resonance is observed in invariant mass of the pKshort system formed in neutrino and antineutrino collisions with nuclei. The mass of the resonance is estimated as (1533+-5)MeV. The observed width is less than 20 MeV, and is compatible with being entirely due to experimental resolution. The statistical significance of the signal is near 6.7 standard deviations. As the position of the observed resonance does not match the mass of any known \Sigma^{*+} state, we believe that it arises from neutrino production of the \Theta^+ pentaquark baryon. The analysis is based on the data obtained in past neutrino experiments with big bubble chambers: WA21, WA25, WA59, E180 and E632.Comment: Institute of Theoretical and Experimental Physics, B.Cheremyshkinskya 25, Moscow 117259, Russi

Antikaon angular distributions in the reaction γd→K−Θ+p→K−K+np{\gamma}d \to K^-{\Theta}^+p \to K^-K^+np near the threshold and the parity of the Θ+{\Theta}^+ pentaquark

Within spectator model we study the reaction ${\gamma}d \to K^-{\Theta}^+p \to K^-K^+np$ in the threshold energy region. We present the predictions for the exclusive and inclusive antikaon angular distributions in the laboratory system for this reaction calculated for two possible parity states of the ${\Theta}^+$ resonance at 1.5 and 1.75 GeV beam energies with and without imposing the relevant kinematical cuts on those parts of the sampled phase space where contribution from the main background sources associated with the ${\phi}(1020)$, ${\Lambda}(1520)$ production as well as with the $K^-p$--rescattering in the final state, is expected to be dominant. We show that under chosen kinematics these distributions are sensitive to the ${\Theta}^+$ parity and, therefore, can be used as a filter for the determination of its parity.Comment: 18 pages, 8 figures; will be published in Phys.Atom.Nucl_4_200

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study

Background: Immediate breast reconstruction (IBR) is routinely offered to improve quality-of-life for women requiring mastectomy, but there are concerns that more complex surgery may delay adjuvant oncological treatments and compromise long-term outcomes. High-quality evidence is lacking. The iBRA-2 study aimed to investigate the impact of IBR on time to adjuvant therapy. Methods: Consecutive women undergoing mastectomy ± IBR for breast cancer July–December, 2016 were included. Patient demographics, operative, oncological and complication data were collected. Time from last definitive cancer surgery to first adjuvant treatment for patients undergoing mastectomy ± IBR were compared and risk factors associated with delays explored. Results: A total of 2540 patients were recruited from 76 centres; 1008 (39.7%) underwent IBR (implant-only [n = 675, 26.6%]; pedicled flaps [n = 105,4.1%] and free-flaps [n = 228, 8.9%]). Complications requiring re-admission or re-operation were significantly more common in patients undergoing IBR than those receiving mastectomy. Adjuvant chemotherapy or radiotherapy was required by 1235 (48.6%) patients. No clinically significant differences were seen in time to adjuvant therapy between patient groups but major complications irrespective of surgery received were significantly associated with treatment delays. Conclusions: IBR does not result in clinically significant delays to adjuvant therapy, but post-operative complications are associated with treatment delays. Strategies to minimise complications, including careful patient selection, are required to improve outcomes for patients

SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort.

Identifying the potential for SARS-CoV-2 reinfection is crucial for understanding possible long-term epidemic dynamics. We analysed longitudinal PCR and serological testing data from a prospective cohort of 4,411 United States employees in 4 states between April 2020 and February 2021. We conducted a multivariable logistic regression investigating the association between baseline serological status and subsequent PCR test result in order to calculate an odds ratio for reinfection. We estimated an odds ratio for reinfection ranging from 0.14 (95% CI: 0.019 to 0.63) to 0.28 (95% CI: 0.05 to 1.1), implying that the presence of SARS-CoV-2 antibodies at baseline is associated with around 72% to 86% reduced odds of a subsequent PCR positive test based on our point estimates. This suggests that primary infection with SARS-CoV-2 provides protection against reinfection in the majority of individuals, at least over a 6-month time period. We also highlight 2 major sources of bias and uncertainty to be considered when estimating the relative risk of reinfection, confounders and the choice of baseline time point, and show how to account for both in reinfection analysis

Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials.

BACKGROUND: Inhaled nitric oxide (iNO) is an effective therapy for pulmonary hypertension and hypoxic respiratory failure in term infants. Fourteen randomized controlled trials (n = 3430 infants) have been conducted on preterm infants at risk for chronic lung disease (CLD). The study results seem contradictory. DESIGN/METHODS: Individual-patient data meta-analysis included randomized controlled trials of preterm infants (5 vs ≤ 5 ppm there was evidence of improved outcome (interaction P = .02); however, these differences were not observed at other levels of exposure to iNO. This result was driven primarily by 1 trial, which also differed according to overall dose, duration, timing, and indication for treatment; a significant reduction in death or CLD (RR: 0.85 [95% CI: 0.74-0.98]) was found. CONCLUSIONS: Routine use of iNO for treatment of respiratory failure in preterm infants cannot be recommended. The use of a higher starting dose might be associated with improved outcome, but because there were differences in the designs of these trials, it requires further examination